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COST-OF-ILLNESS ANALYSIS OF CANDIDEMIA IN PATIENTS ON THE
INTENSIVE CARE UNIT
Heimann S, Cornely OA, Wisplinghoff H, Vehreschild MJ, Franke B, Glossmann J,
Vehreschild J
University Hospital of Cologne, Köln, Germany
OBJECTIVES: Direct and indirect costs caused by candidemia in ICU patients are
currently unknown. We performed an analysis comparing costs depending on the
type of antifungal treatment. METHODS: Data of patients from the University Hos-
pital of Cologne with at least one blood culture positive for Candidaspp. while stay-
ing on the ICU between 2005 and 2010 were documented into a database. Indirect
costs caused by illness-conditioned disability and death before retirement age
were calculated using the friction cost method. Analysis was split for patients
treated with new antifungals (i.e. echinocandins, liposomal amphotericin B, or
voriconazole) or conventional antifungals (i.e. amphotericin B deoxycholate or
fluconazole). RESULTS: Out of 147 identified patients, 45 received new and 66 con-
ventional antifungals, and 36 patients were excluded from analysis (21 died within
96 hours after positive blood culture, seven were rated as contamination, eight
patient files were missing). Mean APACHE IV score was 113 (105.7-121.2) vs. 96
(90.3-100.8, P0,001). Mean direct costs per patient in the new and the conven-
tional antifungal groups were as follows: ICU treatment 24,922 € (95% CI: 17,054-
31,789 €) vs. 17,971 € (95% CI: 13,203-22,740 €,Pn.s.), antifungal treatment 4,271 €
(95% CI: 2,983-5,560 €) vs. 2,079 € (95% CI: 1,246-2,912€, P0.005), total direct costs
41,060 € (95% CI: 30,184-51,935 €) vs. 28,885 € (95% CI: 22,116-35,654 €, n.s.), indirect
costs per patient due to productivity loss of illness-related disability 1,202 € (95% CI:
474-1,930 €) vs. 1,087 € (95% CI: 570-1,604 €, n.s.), due to death before retirement age
1,047 € (95% CI: 236-1,858 €) vs. 1,309 € (95% CI: 584-2,034 €, n.s.). Twenty-five (56%)
and 33 (50%) patients survived hospitalization, 20 (44%) and 22 (33%) patients sur-
vived one year after diagnosis. CONCLUSIONS: Our cost-of-illness analysis shows
the high treatment costs of patients with candidemia. In our analysis, treatment
with new antifungals was associated with higher costs. Although sicker patients
were significantly more likely to receive new antifungals, outcomes were compa-
rable to less sick patients treated with conventional antifungals.
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LENGTH OF STAY AND COST DUE TO RECURRENT CLOSTRIDIUM DIFFICILE
INFECTIONS (CDI) AT A UNIVERSITY HOSPITAL IN FINLAND
Agthe N1, Mattila E2, Purmonen T1, Kanerva M2
1Oy Medfiles Ltd, Kuopio, Finland, 2Helsinki University Hospital, Helsinki, Finland
OBJECTIVES: The European Society of Clinical Microbiology and Infectious Dis-
eases (ESCMID) has highlighted recurrence as the most important problem in the
management of CDI. There is lack of knowledge regarding length of stay (LOS) and
cost associated with recurrent clostridium difficileinfection (CDI). Our objective was
to collect real life data for estimating days of hospitalization and costs attributable
to recurrent CDI. METHODS: A prospective observational study was conducted at
Helsinki University Central hospital during February 2007 and May 2008. The CDI
patients were identified from the microbiology laboratory reports to one of the six
acute wards included in the study. Only health care associated CDI cases were
included. The recurrence of CDI was defined as a new positive sample less than
eight weeks after the first one. The patients had no previous history of CDI one
month prior to first positive sample. Resource use data were extracted from the
medical records using Appropriateness Evaluation Protocol-based methodology.
Unit costs were obtained from literature, hospital administration, laboratory and
pharmacy. RESULTS: During the 16 months study period, 72 CDI patients were
identified, which corresponds to incidence of 0.7-3.8/1,000 patient days. Of those, 7
% were recurrent cases (5 patients). Mean LOS for recurrent cases was 3.17 times
longer than among non-recurrent cases. The mean incremental cost for recurrent
CDI was €6,800 which was 2.52 times higher than the average incremental cost of
the total CDI population (€2,700, and €2,300 for not recurrent cases). Most of the
resource use came from additional treatment days (94% of total cost). Other costs
were due to laboratory tests, medication and isolation. CONCLUSIONS: Recurrent
CDI is associated with significantly longer LOS and higher costs compared to the
average CDI population. The main cost driver between the groups was length of
stay.
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VARICELLA, A COST OF ILLNESS HUNGARIAN STUDY
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OBJECTIVES: Varicella (chickenpox) is one of the most common illness of children,
most typical for the 2-6 years age group. In 2.5% of healthy children complications
occur (bacterial overinfection, meningitis, meningoencephalitis, pneumonia are
the most frequent complications), the infection is potentially life-threatening
among healthy and might be directly life-threatening among immuncompromit-
ted patients. Varicella can be prevented by live attenuated vaccine. According to
WHO recommendation these vaccines are safe, effective and should be imple-
mented into the recommended age-related vaccines. International guidelines rec-
ommend the vaccine, although it is not part of the obligatory vaccination schedule
in Hungary, nor is covered by reimbursement.METHODS: In our research we aimed
to examine the consequences of varicella. We calculated the disease of burden in
Hungary by the utilization of evidences from literature, health care provision data
of Hungarian National Health Insurance Fund Administration as well as question-
naire survey. RESULTS: Direct and indirect costs of varicella-related health care
provision are significant according to our analysis based on HNHIFA data and ques-
tionnaire survey. Our results showed that annually almost 1 billion HUF expendi-
ture caused by varicella. CONCLUSIONS: Our analysis determines the disease bur-
den of varicella and emphasizes the importance of prevention. Increasing the rate
of vaccination, epidemics can be held up, majority of the serious and complicated
cases can be avoided, thus their provisional cost consequence can be decreased.
From the societal viewpoint the costs that can be saved by vaccination are even
higher as remarkable reduction can be achieved in indirect costs due to the rare,
less serious and shorter duration breakthrough cases.
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BURDEN OF DISEASE AND ECONOMIC IMPACT OF DENGUE AND SEVERE
DENGUE IN COLOMBIA: 2011
Castañeda-Orjuela CA1, Diaz H2, Camargo G2, Olarte F2, De la Hoz-Restrepo F1
1Universidad Nacional de Colombia, Bogota, NA, Colombia, 2Universidad Nacional de Colombia,
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OBJECTIVES: About 50 million dengue infections occur every year worldwide. New
dengue vaccines are currently in development and policymakers need appropriate
economic studies to determine their potential impact. This study aims to assess
the burden of dengue disease in Colombia and its costs. METHODS: We estimated
the disease burden of dengue (D) and severe dengue (SD) in Colombia for 2011-2014
based on a dynamic model designed with the best available evidence and validated
with the occurrence data. The annual number of D and SD cases receiving medical
care were determined. We calculated the average cost of care per patient with D
and SD based on a bottom-up costing of cases attended in the Colombian health
facilities, additional costs were estimated from programs of vector control dengue
at different administrative levels. Based on the occurrence of disease and extrap-
olation of national vector control programs we estimated a total annual cost of
burden of dengue in Colombia. RESULTS: Our dengue model estimated in 2011
34,751 D consults (13,900 outpatients, 20,851 inpatients), 988 SD cases, and 102
(78-123) deaths due to dengue. In 2012 22,247 D (8899 in- 13,348 out-patients), 863
SD, and 103 (79-124) deaths. In 2013 27,588 D (11,035 in- 16,553 out-patients), 1032
SD and 105 (80-126) deaths. Finally in 2014 25,957 D (10,383 in- 15,574 out-patients),
913 SD, and 106 (80-127) deaths. The total attention costs in 2011 raised to US$ 16.86
million. That year the total cost of Dengue’s vector program amounted to US$
37.08-42.41 million. The total annual cost of dengue would amount to US$ 53.94-
59.27 million in a year without outbreak. CONCLUSIONS: Burden of dengue disease
in Colombia involves a high economic impact to the health system. In 2011 be-
tween 28.4-31.3% correspond to medical attention cost and between 68.7-71.6% are
due to dengue vector control program.
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OBJECTIVES: Recent randomized, placebo-controlled clinical trials (SPRINT-2; RE-
SPOND-2) demonstrated that the triple combination of peginterferon (PEG), ribavi-
rin (RBV) and boceprevir (BOC) was more efficacious than standard therapy of
PEG-RBV alone in treatment of patients with genotype 1 chronic hepatitis C virus
(GI HCV) infection. The objective of this study was to evaluate the cost-effective-
ness of triple therapy in both treatment-naive and treatment-experienced patients
in Hungary. METHODS: A Markov-model was developed to investigate the long-
term clinical benefits and the cost-effectiveness of the triple therapy from the
Hunagarian payer perspective. Health states within the model were defined using
METAVIR fibrosis scores (F0–F4), decompensated cirrhosis (DC), hepatocellular car-
cinoma (HCC), liver trasnsplant (LT), and liver-realted deaths (LD). Efficacy data was
estimated using SPRINT-2 and RESPOND-2 studies, and disease progression rates
and utilities used in the model were estimated from published studies. Data on
probability of liver-transplantation and cost estimates were based on an analysis of
the Hungarian Sick Fund database.. Costs and benefits were discounted at 5%.
RESULTS: Triple therapy is projected to increase the life expectancy by 0.98 and
2.39 years and the quality-adjusted life years (QALY) by 0.59 and 1.13 in comparison
with treatment with PEG-RBV in treatment-naive and treatment-experienced pa-
tients, respectively. The corresponding incremental cost-effectiveness ratios were
HUF7,747,962 (EUR 26,717) and HUF5,888,240 (EUR20,304) per QALY, respectively.
The lifetime incidence of severe liver disease events (DC, HCC, LT, LD) decreased by
41% and 61% in these patient groups in comparison with treatment with PEG-RBV
alone.CONCLUSIONS: The addition of boceprevir to standard therapy for the treat-
ment of patients with G1 chronic HCV infection in Hungary is cost-effective using
a commonly used willingness to pay threshold of HUF8,48 million (3x GDP per
capita).
PIN33
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OBJECTIVES:Data on actual cost of illness studies for HIV-infection in Germany are
lacking. The objective of CORSAR is to collect comprehensively and prospectively
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data to calculate direct, indirect and intangible costs in patients receiving ART.
METHODS: Multicenter prospective observational study in eight German special-
ized centres for infectious diseases: four private practices/outpatient centres and
four hospitals offering inpatient- and outpatient facilities. CORSAR started recruit-
ment during 2009 and ends in July 2012, when the last patient reaches week 96.
After signing informed consent, patients were included and stratified by treatment
line. Treatment history and concomitant therapy were taken from the patients’
records. Direct costs for hospitalization, outpatient care, other medical care and
treatment as well as out of pocket payments and quality of life data were calculated
from the data collected by quarterly questionnaires. RESULTS: A total of 1154 pa-
tients with a mean age 47.5y receiving ART were included. Time since HIV-diagno-
sis was10.6 years, 10.2% had viral load50 cp/ml; 10.6% female; employment ratio
60.8%. Direct costs of treatment were mainly driven by antiretroviral drugs, ac-
counting for 83.3%. Due to use of less complex ART-regimens and more frequent
use of NNRTI-based ART in earlier treatment lines total costs were highest in ad-
vanced treatment-lines (3rd) with 26,243 €/year compared to 22,718 €/year for
initial therapy. The labour market participation rate also decreases with advance-
ment in treatment lines (65% in first treatment line vs. 46% in3rdtreatment lines).
Indirect cost due to productivity losses account for 7% of total costs.
CONCLUSIONS: Total costs were higher in later lines of therapy due to more com-
plex, less NNRTI-based regimens. In comparison to earlier studies the impact of
Non-ART-costs decreased. Expenses to be borne by the patient increased but are
still less than 1%, indicating an increasing financial burden of people living with
HIV by their disease within the German health system.
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DEVELOPMENT OF TREATMENT COSTS OF PATIENTS UNDERGOING REMISSION
INDUCTION CHEMOTHERAPY: A HISTORICAL COMPARISON BEFORE AND
AFTER INTRODUCTION OF POSACONAZOLE PROPHYLAXIS
Heimann S, Cornely OA, Wisplinghoff H, Vehreschild MJ, Franke B, Glossmann J,
Vehreschild J
University Hospital of Cologne, Köln, Germany
OBJECTIVES: Prior trials have demonstrated efficacy and effectiveness of po-
saconazole in the prophylaxis of invasive fungal diseases (IFDs) in high-risk pa-
tients. Controversy exists about the cost effectiveness of posaconazole prophylaxis
in neutropenic patients with a high risk of IFDs. We performed an analysis com-
paring the direct costs of posaconazole prophylaxis against topical polyene
(thrush) prophylaxis in patients with acute myelogenous leukemia (AML) and my-
elodysplastic syndrome (MDS). METHODS: Data of AML/MDS patients receiving
remission-induction chemotherapy were analysed to compare hospital costs of
patients before (2003-05) and after (2006-08) introduction of posaconazole prophy-
laxis. All cases were part of an earlier analysis demonstrating effectiveness of
posaconazole over topical prophylaxis. Duration on general ward, intensive care
unit, mechanical ventilation, diagnostic procedures and all anti-infective drugs
were included into the cost analysis. RESULTS: Patient groups were well matched
according to age, gender, underlying disease, and duration of neutropenia. The
average costs per patient in the posaconazole group (n76) and the topical polyene
group (n81) were 21,040 € (95% CI: 18,204-23,876 €) and 23,169 € (95% CI: 19,402-
26,937 €) per patient, respectively. Antifungal treatment costs were nominally
higher in the posaconazole group (4,580 € [95% CI: 3,678-5,482 €] vs. 4,019 € [95% CI:
2,825-5,214 €]). Costs for antibacterials (1,316 € [95% CI: 1,039-1,593 €] vs. 1,533 € [95%
CI: 1,238-1,827 €]) were numerically decreased in the posaconazole group. Average
duration of ICU stays were 1.79 (95% CI: 0.68-2.90) days per patient compared to 3.83
(95% CI: 1.53-6.13) days per patient. Costs for diagnostic procedures were 611 € (95%
CI: 478-744 €) and 653 € (95% CI: 552-754 €) per patient, respectively. CONCLUSIONS:
In our hospital, there was a trend towards cost-saving by posaconazole prophylaxis
in patients receiving remission-induction chemotherapy. These cost savings were
primarily caused by a shorter overall length of stay and the less frequent ICU
treatment of patients receiving posaconazole.
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COST OF ANTIMICROBIAL PRESCRIBING USING A LARGE PHARMACY
DATABASE IN SOUTH AFRICA
Truter I
Nelson Mandela Metropolitan University, Port Elizabeth, Eastern Cape, South Africa
OBJECTIVES: To provide a general overview of antimicrobial prescribing cost in a
South African primary care patient population whose prescriptions were dis-
pensed by community pharmacies. METHODS: A retrospective, cross-sectional
pharmacoepidemiological study was conducted on prescription data of a national
community pharmacy group in South Africa for 2010. All records for antimicrobials
were analysed. The MIMS classification system was used. RESULTS: A total of 660
500 patients received 1 576 593 antimicrobial products during 2010 (average of 2.39
products per year) at a total cost of R191 875 007. The average age of patients was
34.23 years. Most patients were females (58.32%), and they were prescribed 60.12%
of antimicrobial products. The average cost per antimicrobial product was R121.70
(SDR158.21). Antiviral agents were the most expensive (R195.67), followed by ami-
noglycosides (R188.42). The least expensive products were chloramphenicols
(R17.25) and sulphonamides and combinations (R22.68). Beta-lactams were the
most often prescribed class accounting for 36.02% of all antimicrobial prescrip-
tions. The average cost for a beta-lactam prescription was R99.53. The average cost
per over-the-counter product was R32.75, compared to R158.21 for prescription-
only antimicrobials. Most products were tablets (61.80%), followed by capsules
(16.25%) and suspensions (14.39%). Per prescription, the injections were the most
expensive (average of R343.85 per prescription), followed by ampoules (R324.56)
and solutions (R267.33). Creams were on average the least expensive (R31.24).
There was a clear peak in prescribing during the winter months (May to August).
The single most often prescribed trade name product was a generic combination
product of amoxicillin and clavulanic acid. On average, the most expensive trade
name product was Valcyte 450R tablets (valganciclovir) at R12 217.76.
CONCLUSIONS: This study provided a general overview of antimicrobial prescrib-
ing cost in a South African primary care patient population. Costs varied hugely
with generic prescribing influencing costs.
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SIX YEARS OBSERVATIONAL STUDY OF THE COST OF HIGHLY ACTIVE
ANTIRETROVIRAL THERAPY AND HIV/AIDS CONTROL
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OBJECTIVES: To analyze the changes in the highly active antiretroviral pharmaco-
therapy during the period 2006-2011 and its impact on cost and disease control of
HIV/AIDS patients in Bulgaria. METHODS: It is a combined retrospective and pro-
spective observational real life study on cost and therapeutic results of AIDS pa-
tient’s therapy. Information was gathered for 2/3 of the treated patients for the
antiretroviral combinations therapy and its cost, CD4 count and viral load. The
changes in the dosage regimes, cost of therapy and its influence on CD4 count and
viral load were evaluated. Descriptive statistic, Willcoxon tests, and Spearman
correlation analysis were applied. RESULTS: On total 162 patients were included
and out of them 48 identified with the changes in their therapy. Nearly 40 different
dosage regimes were found prescribed as combinations of 3 or 4 medicines. During
the period were introduces 3 new antiretroviral medicines (tenofovir, emtricit-
abine, darunavir). The average yearly cost of pharmacotherapy is increasing from
155 837.64 euro to 319 571.76 euro during 2006 - 2011. To all treatment naive pa-
tients were prescribed the newly authorized medicines that lead to sustained sup-
pression of viral load to20 in 45.46%. Introduction of the new medicines led to the
increase in total pharmacotherapy cost with 291 89.64 euro, but also to better
disease control. Statistically significant were the changes in the mean cost of ther-
apy in 2007 vs 2006 (p0,0002) and in 2010 vs 2009 (p 0,0001). We found the
statistically significant changes among the mean cost of therapy and viral load
(p0,0221), as well as among the mean cost of therapy and CD4 count (p0,05). The
correlation among the therapeutic results and the therapeutic combinations were
found in 2011 (p0,0064).CONCLUSIONS:AIDS remain costly disease for the health
insurance budget but new medicines led to better control on its progression.
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THE ECONOMIC BURDEN OF INITIAL EMPIRIC ANTIBIOTIC FAILURE ON HEALTH
CARE RESOURCE UTILIZATION FOR HOSPITALIZED PATIENTS WITH
COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAIS) IN GREECE
Athanasakis K1, Petrakis I2, Tsoulas C2, Vatopoulos A1
1National School of Public Health, Athens, Greece, 2Pfizer Hellas, Athens, Greece
OBJECTIVES: To estimate the impact of initial empiric antibiotic treatment failure
on pharmacological and total health care costs in hospitalized patients with cIAIs.
METHODS: The economic impact associated with initial empiric antibiotic treat-
ment failure was based on the results of an observational epidemiological study
involving 201 adults with cIAI in Greece (NCT00929643). An average per patient-per
day DRG value was estimated based on diagnosis at discharge and DRG mapping.
Daily cost was then extrapolated to the additional length of stay (LOS), associated
with initial antibiotic failure. Costs included expenditure for additional ICU and
surgical interventions. DRG matching was validated by a specialist medical advi-
sor. Mean per patient DRGs were weighed against subject percentage in each diag-
nosis group. Mean per patient costs for unsuccessful initial therapies were calcu-
lated using the latest formulary prices and the mean number of days on each
antibiotic agent, as recorded in the observational study. RESULTS: The most fre-
quently reported diagnoses (201 subjects) were perforation of the intestine (15.9%),
acute appendicitis with peritoneal abscess (13.4%) and post–operative peritonitis
(13.4%). Patients most commonly received metronidazole (59.2%), followed by
b–lactamase inhibitors (38.3%) and second generation cephalosporines (30.3%) as
empiric antibiotic treatment (as part of monotherapy, double therapy or triple
therapy schemes). 78 patients exhibited failure of the initial treatment, whereas
initial treatment was successful in 111 subjects with respective hospitalization of
21.916.4 and 8.9  4.5 days. Total additional per patient resource cost was esti-
mated to be €3,761.56 inclusive of unsuccessful mean empiric antibiotic expendi-
ture, which was estimated to be €220.06 per patient. CONCLUSIONS: Retrospective
data collected for a 2-year period showed that a significant percentage (42.9%) of
patients exhibited failure of their initial antibiotic treatment. These patients had a
greater chance of requiring prolongation of hospitalization and more extensive use
of health care expenditure during times where resources are scarce.
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